Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
Linear hypertrophic scar is a common surgical problem that can be difficult to manage,
especially for the median sternotomy scar. Despite high demand for the early intervention to
prevent and treat surgical scars, there is yet no universal consensus on satisfactory
treatment. Botulinum toxin type A is a neurotoxin that has been widely and safely used in
medicine for more than 30 years. It induces chemodenervation through acting on the
presynaptic neuron to prevent release of acetylcholine, which leads to functional denervation
of striated muscle for about 6 months after injection. The aim of this randomized controlled
trial is to evaluate the efficacy of Botulinum toxin type A as a prophylactic treatment in
the early postoperative of median sternotomy for the purpose of preventing excess scar
formation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Xijing Hospital
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA